At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Peter Hillmen (Leeds General Infirmary, UK) about recent advances in the research of chronic lymphocytic leukaemia (CLL).
The understanding of CLL biology is changing how the disease is managed. Prognostic markers help to identify specific patient subgroups and provide insight disease progression in these groups. New studies in drugs, such as ibrutinib, target cell proliferation.